H
Hazal Ozlen
Researcher at Douglas Mental Health University Institute
Publications - 10
Citations - 86
Hazal Ozlen is an academic researcher from Douglas Mental Health University Institute. The author has contributed to research in topics: Medicine & Cognitive decline. The author has an hindex of 1, co-authored 3 publications receiving 19 citations.
Papers
More filters
Journal ArticleDOI
Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
Pierre-François Meyer,Nicholas J. Ashton,Thomas K. Karikari,Cherie Strikwerda-Brown,Theresa Köbe,Julie Gonneaud,Alexa Pichet Binette,Hazal Ozlen,Yara Yakoub,Joel Simrén,Josef Pannee,Juan Lantero-Rodriguez,Anne Labonté,Suzanne L. Baker,Michael Schöll,Eugeen Vanmechelen,John C.S. Breitner,Henrik Zetterberg,Kaj Blennow,Judes Poirier,Sylvia Villeneuve +20 more
TL;DR: Novel plasma p‐tau231 and p-tau181 assays as indicators of tau and Aβ pathologies measured with positron emission tomography (PET) and their association with cognitive change, in cognitively unimpaired older adults are evaluated.
Journal ArticleDOI
Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
Melissa McSweeney,Alexa Pichet Binette,Pierre-François Meyer,Julie Gonneaud,Christophe Bedetti,Hazal Ozlen,Anne Labonté,Pedro Rosa-Neto,John C.S. Breitner,Judes Poirier,Sylvia Villeneuve +10 more
TL;DR: Relatively low FTP-PET SUVRs are associated with pathologic markers of AD in the preclinical phase of the disease and should be considered, depending on the purpose of the tau classification.
Journal ArticleDOI
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Cherie Strikwerda-Brown,Diana A. Hobbs,Julie Gonneaud,Frédéric St-Onge,Alexa Pichet Binette,Hazal Ozlen,Karine Provost,Jean-Paul Soucy,Rachel F. Buckley,Tammie L.S. Benzinger,John C. Morris,Victor L. Villemagne,Vincent Dorcet,Reisa A. Sperling,Keith A. Johnson,Christopher C. Rowe,Brian A. Gordon,Judes Poirier,John C.S. Breitner,Sylvia Villeneuve +19 more
TL;DR: The clinical prognostic value of NIA-AA research criteria was confirmed in 4 independent cohorts, with most A+T+(N+) older individuals without cognitive impairment developing AD symptoms within 2 to 3 years.
Posted ContentDOI
AT(N) predicts near-term development of Alzheimer's disease symptoms in unimpaired older adults
Cherie Strikwerda-Brown,Julie Gonneaud,Derek Hobbs,Frédéric St-Onge,Alexa Pichet Binette,Hazal Ozlen,Karine Provost,Jean-Paul Soucy,Rachel F. Buckley,Tammie L.S. Benzinger,John C. Morris,Victor L. Villemagne,Vincent Dorcet,Reisa A. Sperling,Keith A. Johnson,Christopher C. Rowe,Brian A. Gordon,Judes Poirier,Jcs Breitner,Sarah-Christine Villeneuve,Aibl,Knight ADRC,Habs,PREVENT-AD +23 more
TL;DR: In this paper , the clinical value of these biological criteria for prediction of near-term cognitive impairment in cognitively unimpaired older individuals was assessed using temporal cortical thickness, which was confirmed in four independent cohorts, with nearly all A+T+ individuals developing AD symptoms within 2-3 years.
Journal ArticleDOI
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Hazal Ozlen,Alexa Pichet Binette,Theresa Köbe,Pierre-François Meyer,Julie Gonneaud,Frédéric St-Onge,Karine Provost,Jean-Paul Soucy,Pedro Rosa-Neto,John C.S. Breitner,Judes Poirier,Sylvia Villeneuve +11 more
TL;DR: A longitudinal multicentric cohort study as mentioned in this paper investigated the timing at which Aβ-PET binding starts showing associations with other markers of Alzheimer disease and found that participants with widespread amyloid binding exhibited significant cognitive decline.